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Abstract
Tyrosine kinase inhibitors (TKIs) have been in use as cancer therapeutics for nearly a decade, and their utility in
targeting specific malignancies with defined genetic lesions has proven to be remarkably effective. Recent efforts
to characterize the spectrum of genetic lesions found in non–small cell lung carcinoma (NSCLC) have provided
important insights into the molecular basis of this disease and have also revealed a wide array of tyrosine kinases
that might be effectively targeted for rationally designed therapies. The findings of these studies, however, also
provide a cautionary tale about the limitations of single-agent therapies, which fail to account for the genetic
heterogeneity and pathway redundancy that characterize advanced NSCLC. Emergence of drug resistance mech-
anisms to specific TKIs, such as gefitinib and erlotinib, suggests that more sophisticated chemotherapeutic para-
digms that target multiple pathways at the same time will be required to effectively treat this disease.
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Introduction
Recent large-scale efforts to characterize the genetic basis of cancer
have provided significant insights into the etiology of this disease
[1–7]. Sequencing of several distinct “cancer genomes” has confirmed
the importance of key tumor suppressors and oncogenes, but it has
also turned up an abundance of additional mutations that have yet to
be characterized with regards to their transforming potential and ef-
fect on tumor behavior during disease progression. Although most of
these mutations are likely to be nonfunctional sequence changes, a
significant number of them undoubtedly play important roles in tu-
mor initiation and progression. The remarkable variation in muta-
tional profiles seen across patient samples suggests that each tumor
represents a distinct disease state that can only be effectively treated
with precision therapy that targets the specific combination of ge-
netic changes unique to each tumor.
This concept of “personalized medicine” has found particular trac-
tion in the treatment of non–small cell lung carcinoma (NSCLC),
which is one of the best-characterized solid tumor types owing to
its high rate of incidence in Western society [8–12]. Even before
the advent of genome sequencing, many of the more common ge-
netic alterations that characterize NSCLC had been discovered by
traditional molecular biology approaches [13–15]. One theme that
emerged from this work was the prevalence of genetic alterations
to key growth factor signaling pathways that regulate cell prolifera-
tion, survival, and migration [3,12]. These pathways largely depend
on signal propagation by kinase cascades, suggesting that they would
be excellent targets for rationally designed chemotherapies aimed at
the inhibition of kinase enzymatic function.
One of the more effectively targeted classes of kinases to date has
been the tyrosine kinase family of signaling enzymes (Figure 1). This
large class of molecules includes both receptor and nonreceptor pro-
tein tyrosine kinases and has been extensively reviewed in many ex-
cellent articles elsewhere [16–18]. Several members of this kinase
family have been successfully targeted for treatment of a relatively
narrow range of solid and hematologic malignancies, suggesting that
further development of novel tyrosine kinase inhibitors (TKIs) may
be useful for targeting a broader assortment of tumor types [19].
Whereas this approach to cancer therapy has undoubtedly provided
some significant success stories, it has also highlighted the inherent
difficulty of treating genetically heterogeneous patient populations
with targeted therapeutics. In this review, we will discuss the various
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TKIs that have been used for the treatment of NSCLC or are cur-
rently undergoing clinical validation, as well as the resistance mecha-
nisms that have limited the success of these drugs in the clinic. Finally,
we will also discuss future prospects of TKI in the treatment of
NSCLC and suggest how these drugs may be used for successful per-
sonalized therapies.
The Genetic Basis of Primary Resistance to
TKIs in NSCLC
Use of rationally targeted therapies for cancer treatment by defini-
tion presumes that the specific target of interest has been correctly
identified. In the case of single agent therapies, the default assump-
tion is that hitting a single target—or at least a narrow range of de-
fined targets—will be sufficient to treat a given tumor. This model of
“oncogene addiction” has gained wide acceptance with the identifica-
tion of single mutational events that both initiate and maintain trans-
formation in most patients with a specific subtype of cancer [20–22].
Examples of this phenomenon include the BCR-ABL translocation in
chronic myelogenous leukemia and the ERBB2/Her2 mutations in
breast cancer [23,24]. Treatment of these cancers with single-agent
TKIs targeted at BCR-ABL or ERBB2, respectively, has shown re-
markable efficacy in the clinic, and it leads to the hope that correct
identification of driving mutations in other cancers will yield similar
results [25–27].
Figure 1. Genetic alterations of the tyrosine kinase family in non–small cell lung cancer. Alignment of all tyrosine kinases encoded in the
human genome according to the similarity of their kinase domains reveals a unique pattern of mutagenic changes associated with non–
small cell lung carcinoma. Significant genetic alterations tend to occur in multiple members of individual kinase subfamilies, with re-
ceptor tyrosine kinases being more commonly mutated than NRTKs. Genetic alterations include amplification (red font), deletion (blue
font), and point mutation (asterisk), all of which have been identified at significant rates in primary patient samples. See Table 1 for
statistical evaluation of copy number changes.
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The findings of recent tumor genome sequencing studies—as well
as the results of manifold clinical trials—unfortunately suggest that
hope for broadly successful monotherapy in NSCLC may be largely
unfounded [3,28]. These studies have clearly demonstrated that no
single genetic event occurs in more than 15% to 20% of the patient
population and that most patients instead display a unique combina-
tion of mutations to several known oncogenes and tumor suppres-
sors. This is particularly true of potential tyrosine kinase targets, of
which more than 30 different molecules have been reported to be
amplified or mutationally activated in NSCLC (Figure 1) [2–5]. Al-
though a few kinase mutations are certainly more common than
others—for example, mutations to epidermal growth factor receptor
(EGFR)—these mutations rarely occur in isolation and may be com-
pensated for by genetic alterations to other RTKs and/or downstream
effectors [29].
In this context, it has become increasingly clear that the central
mechanism of primary resistance to TKI therapy in NSCLC is the
heterogeneity and mutational redundancy of this disease. In geneti-
cally undefined patient populations, a given molecular target may
only be present in the tumors of a small percentage of patients. Fur-
thermore, even when the target is present, it may not be absolutely
necessary for tumor maintenance, especially in patients with ad-
vanced disease. This finding likely underlies the poor response rate
of NSCLC to most targeted therapies, which rarely exceeds a 5% to
10% objective response rate in patients with advanced disease [9,12].
Unfortunately, most clinical trials are designed around the use of sin-
gle agents in genetically undefined patient populations, making it
highly unlikely that any given drug will achieve a statistically signif-
icant response during the study. In fact, such designs are inherently
flawed because the overall benefit to a small fraction of eligible sub-
jects is diluted over a nonselected population, thus skewing the result
of such a randomized study toward incorrect conclusion about a
given therapy [30].
Framework for Genetic Classification of
Therapeutic Subgroups in NSCLC
As stated above, the success of rationally targeted therapies—including
TKI—depends heavily on the correct identification of key driver
mutations in each patient. In the absence of reliable genetic informa-
tion, patients diagnosed with NSCLC can be directed toward the best
therapy based on the histology (squamous vs adenocarcinoma) and
natural histology (age, smoking status) of their disease. Because the
prevalence of specific driver mutations in NSCLC varies dramatically
in tumors with different histologies and natural histories, use of these
criteria is helpful in eliminating treatments that are unlikely to succeed.
For example, patients with squamous cell tumors are poor candidates
for first-line EGFR inhibitor therapy because this tumor type rarely
contains activating EGFR mutations and is more likely to respond
to standard platinum-based therapies than targeted agents currently
available [31].
When genetic information is available in addition to tumor histol-
ogy and patient history, more reliable and precise decisions can be
made regarding the choice of targeted therapy for NSCLC patients.
This is particularly true for patients with the more common adeno-
carcinoma histology, which is consistently characterized by distinct
driver mutations that can be broadly segregated into three classes:
1) tumors with activating mutations and/or amplification of growth
factor receptor tyrosine kinases (RTKs), 2) tumors with activating
mutations of the KRAS oncogene, and 3) tumors with EML-ALK
fusions. Although this classification scheme is clearly too simplistic
in that it ignores mutations to other well-defined tumor suppressors
(PTEN, LKB1) and oncogenes (PIK3CA, BRAF ), it provides a reli-
able framework for the classification of most NSCLC. Furthermore,
the three classes in this framework tend to be mutually exclusive,
whereas mutations to other known tumor suppressors and oncogenes
are commonly found across all three classes [3,32–34].
Proper segregation of patients into one of these three classes has
significant implications for targeted therapy and for primary resis-
tance to these therapies. For instance, use of an EGFR TKI to treat
a KRAS or EML4-ALK driven tumor will almost certainly result in a
poor outcome [35]. In an unselected patient population, this result
would be classified as primary resistance, whereas in a genetically
defined NSCLC population, it would be considered a successful
negative control. On the basis of this example, it is clear that more
complete genetic data are required for the advancement of targeted
therapy, particularly when a relatively selective kinase inhibitor is be-
ing used.
Assuming that NSCLC patients can be properly segregated into
the classes noted above based on genetic data, the next question that
clinicians must address is what therapy should be used to treat each
class of tumors. Activating KRAS mutations are the single most com-
mon genetic driver in lung cancer, represented about 15% to 20% of
all NSCLCs [3,32,35]. Attempts to target activated Ras variants have
historically failed for a wide variety of reasons, and despite decades of
research on this oncogene, there is no clear answer for how to treat
mutant Ras-driven tumors [36]. The most promising avenues for
treating this class of cancers lie in targeting the downstream signaling
effectors or metabolic byproducts of Ras transformation, although
these targets tend to be highly cancer-specific [37,38]. New advances
in targeting Ras-driven tumors have been reviewed elsewhere and will
not be extensively discussed in this review [36,39].
The two other known classes of NSCLC collectively depend on
activating mutations to a variety of tyrosine kinases, including both
receptor and nonreceptor members of this family (Figure 1 and Ta-
ble 1). This population of tumors represents anywhere from 40% to
80% of all NSCLCs, which implies that up to 175,000 new lung
cancer patients each year in the United States alone could benefit
from some form of targeted TKI therapy, provided that the correct
target for each tumor could be identified [40]. This alone is a daunt-
ing task because more than 30 different tyrosine kinases have been
implicated in the cause of NSCLCs (Figure 1 and Table 1). With
faster and more accessible genome sequencing technologies on the
horizon, however, identifying the correct targets for TKI therapy is
becoming increasingly tangible.
The remainder of this review will focus on TKIs that have been
introduced into the clinic or are in clinical testing, with a specific
emphasis on their performance in clinical trials and on the under-
standing of resistance mechanisms that will aid in the refinement
of TKI therapy.
Growth Factor Receptor TKIs
EGFR Inhibitors
The most well-studied small-molecule TKIs used for treatment of
NSCLCs are the quinazoline class of compounds targeted to EGFR.
Two drugs in this class, erlotinib and gefitinib, were approved for the
treatment of NSCLC in 2004 and 2005, respectively (Figure 2A).
Since then, several thousand patients have received these drugs as
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first-, second-, or third-line therapy, providing a large amount of clin-
ical data for retrospective analysis of drug efficacy [41,42].
Initial studies with erlotinib and gefitinib in unsegregated patient
populations demonstrated a relatively low objective response rate
(8%-9%), which was somewhat surprising given the strong efficacy
of these drugs in preclinical models and the high prevalence of EGFR
overexpression in lung cancer [43,44]. In the past 5 years, it has
become increasingly clear that patients who respond well to these
drugs almost universally display tumors with activating mutations to
EGFR. More specifically, activating mutations involving exon 19 dele-
tions or exon 21 point mutations were found to be particularly sen-
sitive to these drugs and were strong predictors of patient outcome in
EGFR TKI therapy [41,45]. Nevertheless, patients’ tumors that dis-
play elevated expression of wild-type EGFR generally fail to show
radiographic responses to treatment with these agents, suggesting
that careful genetic prescreening of patients for specific EGFR muta-
tions will be required to gain full advantage in the clinic [46,47].
As is the case in most advanced cancers, NSCLC patients on EGFR
inhibitor therapy who initially respond to treatment eventually develop
secondary resistance, in this case with a median progression-free sur-
vival time of 8 to 10 months [28,48,49]. Several mechanisms to ac-
count for secondary resistance to EGFR TKI have been elucidated,
providing new insights into how anti-EGFR therapy might be im-
proved in the future. These mechanisms and their implications for
NSCLC treatment are briefly detailed below.
Resistance Mechanism 1: Secondary Mutations to EGFR
One of the more common mechanisms of kinase inhibitor resistance
is the acquisition of secondary mutations to the target kinase. This
mechanism has been previously demonstrated in chronic myelogenous
leukemia patients bearing the BCR-ABL fusion oncogene, who even-
tually develop resistance to the TKI imatinib after prolonged periods
of stable disease [50,51]. In the case of NSCLC patients, resistance
to EGFR TKI therapy has been observed in the presence of primary
or secondary point mutations to exon 20 of EGFR (Figure 2B). The
most common of these mutations—T790M—decreases the affinity
Table 1. Significant CopyNumber Changes of Key Tyrosine Kinases inNon–Small Cell Lung Cancer.
Name Family GISTIC Score (q) Frequency (%)
Significantly amplified
EGFR EGFR 9.29e − 25 10.0
FGFR1 FGFR 3.61e − 23 10.8
INSRR InsR 3.29e − 12 15.4
TRKA Trk 3.29e − 12 15.6
HER2/ErbB2 EGFR 9.76e − 10 10.9
FAK Fak 1.61e − 06 12.2
PDGFRa PDGFR 4.67e − 04 8.9
HER3/ErbB3 EGFR 6.98e − 04 12.0
MET Met 1.08e − 03 6.8
KIT PDGFR 1.29e − 03 8.9
IGF1R InsR 1.75e − 03 10.9
FLT4 VEGFR 1.99e − 03 10.5
KDR VEGFR 3.84e − 03 8.5
FGFR4 FGFR 8.80e − 03 10.4
LMR2 Lmr 9.02e − 03 7.6
EphB4 Eph 4.10e − 02 7.2
TIE1 Tie 5.26e − 02 4.2
FES Fer 7.71e − 02 8.9
Significantly deleted
LTK Alk 5.34e − 11 9.3
TIE2 Tie 2.37e − 08 6.1
TYRO3 Axl 3.48e − 08 9.1
JAK2 JakA 4.08e − 06 4.2
SRM Src 1.74e − 05 8.1
FGR Src 3.67e − 05 7.8
EphB2 Eph 3.70e − 05 8.1
EphA8 Eph 6.55e − 05 7.9
LMR3 Lmr 2.51e − 04 7.2
EphA2 Eph 4.19e − 04 7.2
EphA7 Eph 3.68e − 02 4.4
FER Fer 3.90e − 02 4.1
TEC Tec 5.26e − 02 4.2
LYN Src 7.26e − 02 4.0
EphA3 Eph 7.82e − 02 3.4
FGFR2 FGFR 8.41e − 02 4.9
ACK Ack 1.91e − 01 4.2
HER4/ErbB4 EGFR 1.97e − 01 4.8
Copy number variation (CNV) of tyrosine kinases in NSCLC was assessed using the GISTIC
algorithm and SNP array data obtained from the Broad Institute Tumorscape program [2,5].
The significance of amplification or deletion was assessed for all human tyrosine kinases. Those
exceeding the GISTIC significance score (q) of 0.25 are included in each table. Frequency values
indicate the percentage of 384 non–small cell lung cancer samples that contain focal amplification
or homozygous deletion of the indicated tyrosine kinase.
Figure 2. Resistance to EGFR inhibitors mediated by gatekeeper residue mutations. (A) Chemical structures of erlotinib and gefitinib,
both of which are members of the quinazoline class of EGFR inhibitors. (B) The crystal structure of erlotinib bound to EGFR demon-
strates its physical orientation within the ATP binding pocket of the enzyme. Both erlotinib and gefitinib function as competitive inhib-
itors by preventing the binding of ATP into this cleft. The threonine at position 790, commonly referred to as a “gatekeeper” residue
owing to its location within the binding pocket, is commonly altered in NSCLC. Mutation of this residue to methionine (T790M) prevents
incorporation of both erlotinib and gefitinib owing to steric constraints induced by decreased pocket size. Structure information was
obtained from Research Collaboratory for Structural Bioinformatics (accession number: PDB 1M17) [55].
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of TKI for the receptor, thus rendering tumors insensitive to chemo-
therapy [52–55].
Because exon 20 point mutations may occur as the primary or sec-
ondary mechanism for constitutive EGFR activation in NSCLC,
drugs that can inhibit EGFR kinase activity in the presence of these
and other activating mutations, while leaving wild-type EGFR un-
affected, have become a major area of focus for TKI development
[56,57]. Promising results with a new pyrimidine-based class of drugs
that meet these criteria have recently been reported in preclinical
models, suggesting that improved EGFR TKI therapies may soon
be available [58].
Resistance Mechanism 2: Activation of
Compensatory Oncogenes
In addition to being a key form of primary resistance, amplification
and/or mutation of oncogenes with redundant function to EGFR have
emerged as another key mode of resistance to EGFR TKI. The best-
characterized mechanism of this type is amplification of MET, another
RTK that has been implicated in a wide range of solid tumors, includ-
ing NSCLC [59]. Recent data suggest that cells harboring low-level
MET amplification may exist in patients with EGFR-driven tumors
and that these cells are heavily selected for after long-term treatment
with erlotinib or gefitinib [60]. Emergence of drug-resistant secondary
tumors is particularly accelerated in the presence of the MET ligand
hepatocyte growth factor, which has also been shown to be amplified
or overexpressed in many solid tumors.
Activation of other RTK with similar redundancy to EGFR may
also play an important role in acquired resistance to EGFR TKI (Fig-
ure 1 and Table 1). Insulin-like growth factor receptor (IGF1R), for
instance, has been shown to mediate resistance in cultured lung can-
cer cells and is known to be amplified in a subset of NSCLC [61,62].
Although no solid evidence for compensation of EGFR inhibition
by RTKs other than MET and IGF1R has been reported to date,
it is likely that current large-scale sequencing studies of EGFR TKI-
resistant tumors will uncover similar compensatory mechanisms by
RTK or other signaling oncoproteins [29,63,64]. Identification of
these compensatory oncoproteins will provide new targets for com-
bined treatment that may be used to prevent the emergence of TKI-
resistant cell populations from EGFR TKI-sensitive tumors.
It is important to note that activating mutations to KRAS—although
an important mode of primary resistance—have not been associated
with secondary resistance to EGFR TKI [32,35,65]. Although more
studies are required to confirm that KRAS activation is insufficient
to compensate for loss of EGFR activity, this observation is consistent
with differences in the natural history of KRAS-mutant and EGFR-
mutant tumors, which are differentially enriched in smokers and non-
smokers, respectively [47,66]. Both findings suggest that the EGFR
and K-Ras oncoproteins are not redundant with respect to the molec-
ular mechanisms by which they induce and maintain transformation.
As such, it might be predicted that efforts to target signaling path-
ways required for RTK-driven tumors will fail in patients with Ras-
driven tumors—and vice versa—owing to the nonoverlapping modes
of transformation used by these oncoproteins.
Resistance Mechanism 3: Epigenetic Identity Switching
Perhaps the most interesting mechanism for EGFR TKI resistance
that has been uncovered to date is described in a recent report by
Sharma et al [67]. In their study, the authors exposed EGFR TKI-
sensitive cell lines to gefitinib for several weeks and then selected the
subclones that emerged from this treatment for in vitro expansion.
Surprisingly, the various cell lines selected by this method seemed
to have developed stable resistance to EGFR TKI by undergoing a
multistep process of nonrandom epigenetic switching to an alter-
native cellular identity. This identity did not seem to be due to com-
pensatory genetic changes in other RTK and was reversible after
several passages in TKI-free medium.
Whereas the underlying mechanism(s) that allow NSCLC cells to
transiently change their cellular identity are incompletely understood,
it is clear that identity switching can be prevented by inhibition of
histone deacetylases (HDACs), which are responsible for mediating
the nonrandom changes in gene expression observed in EGFR TKI-
resistant cells. The epigenetic switch also seems to depend on signaling
through the IGF1R, suggesting that activation of an alternate RTK to
EGFR may be a key feature of both genetic and epigenetic resistance
mechanisms [67]. Further studies in patient-derived tumor samples
and a broader array of cell lines will be required to determine the ex-
tent to which this mechanism actually occurs in EGFR TKI-resistant
NSCLC; although based on results in drug-resistant cell lines derived
from other cancer types, it seems that coordinate treatment of tumors
with cytotoxic or targeted agents and HDAC inhibitors may present
a feasible method to prevent the emergence of drug resistance tu-
mor subclones.
It is worth noting that the drug-resistant cells described by Sharma
et al. are reminiscent of tumor-initiating cells—also known as cancer
stem cells (CSCs)—which have been identified in a variety of solid
tumors [68,69]. Both cell types exist as a small population of slow-
cycling, self-renewing tumor cells that are significantly more resistant
to both cytotoxic and targeted therapy than other tumor cells [70,71].
Although it was initially thought that CSCs exist as a stable popula-
tion in solid tumors, it has been recently shown that the CSC identity
may instead represent a reversible state that is transiently maintained
by a small population of cells in a given tumor [72]. Interestingly, the
phenotypic switching mechanisms for CSCs and TKI-resistant cells
seem to be driven by similar epigenetic mechanisms involving the
JARID family of chromatin-modifying proteins. These findings sug-
gest that reversion of tumor cells to a CSC-like cellular identity may
represent a universal drug resistance mechanism that must be ac-
counted for regardless of the chemotherapeutic regimen being used
for cancer treatment.
MET Inhibitors
Owing to its role in EGFR TKI resistance and as a primary driving
oncogene in several solid tumors, MET has become a key target of
interest for rationally designed chemotherapy [73,74]. Although MET
kinase inhibitors have yet to be approved for use by the Food and
Drug Administration, several different agents are being tested in clin-
ical trials alone or in combination with EGFR TKI for the treatment
of NSCLC (Table 2). These agents include drugs that are specifically
targeted to MET, as well as drugs that target both MET and other
cancer-associated RTKs [75].
Clinical data regarding resistance to MET inhibitors have yet to be
thoroughly documented, although an in vitro study using the selec-
tive MET inhibitor PHA-665257 to derive tumor cell lines with sec-
ondary resistance has been performed [76]. Data from this study
suggest that resistance to MET inhibition is driven by the emergence
of EGFR pathway alterations, either at the level of EGFR itself or at
the other receptors from the ERBB family of RTKs. This finding pro-
vides additional confirmation of the functional redundancy between
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MET and ERBB family receptors and also underscores the clinical
importance of targeting both classes of RTKs simultaneously to pre-
vent the acquisition of secondary resistance to TKI therapy.
Anaplastic Lymphoma Kinase Inhibitors
Anaplastic lymphoma kinase (ALK) is an RTK that has been pre-
viously implicated in a number of solid and hematologic malignan-
cies, most prominently anaplastic large cell lymphoma (ALL) and
neuroblastoma [77,78]. Like EGFR and MET, ALK may be ampli-
fied or point mutated to achieve activation. In addition, ALK can also
be activated by chromosomal rearrangements, as is the case in sub-
sets of ALL and NSCLC [34,79]. Whereas ALL-associated rearrange-
ments primarily involve chromosomal translocation that result in the
fusion of ALK to the various nuclear or cytoplasmic proteins such as
nucleophosmin (NPM1), NSCLC-associated rearrangements more
commonly involve small chromosome 2p inversions that link the C-
terminal intracellular kinase domain of ALK to the N-terminal do-
main of the microtubule-associated protein EML4 [80]. The resulting
fusion protein is constitutively active because of autodimerization, mak-
ing it highly oncogenic and capable of independently transforming
NIH-3T3 fibroblasts based on xenograft assays.
NSCLC cell lines harboring EML4-ALK fusions are highly sensi-
tive to ALK TKI in vitro, providing strong evidence that this genetic
rearrangement is the primary driving force for their transformation
[81]. Interestingly, EML4-ALK translocations are found in roughly
4% of all NSCLC but are particularly enriched (9.4%) in younger
patients with no history of smoking [82,83]. Owing to this relatively
high prevalence and encouraging preclinical data in cell culture mod-
els, ALK TKIs are rapidly being introduced into the clinic in parallel
with genetic screening for chromosome 2 rearrangements that pro-
duce the EML4-ALK fusion. Early reports suggest that patients with
these genetic lesions respond favorably to the dual TKI crizotinib,
which selectively targets both ALK and MET [34,84,85]. Ongoing
clinical trials will provide a more complete picture of the efficacy and
durability of patient responses to ALK TKI therapy in the near fu-
ture [86].
Other RTK Targets in Clinical Development for
NSCLC Therapy
Although tumors bearing amplification and/or mutation of EGFR,
MET, and ALK represent the largest and best-characterized cohort of
RTK-driven NSCLC, large-scale sequencing studies have demonstrated
that several other growth factor receptors are recurrently mutated as
well (Figure 1). These include IGF1R, stem cell factor receptor
(SCFR/KIT) and members of the fibroblast growth factor receptor
(FGFR), neurotrophin receptor (NTRK), and ephrin receptor (EPHA
and EPHB) families [3,87,88]. TKIs that target several of these RTKs
are in early stages of clinical testing for NSCLC treatment, although
results of these studies have yet to be reported (Table 2). Providing that
these drugs are able to sufficiently inhibit their targets at pharmacolog-
ically relevant doses and with limited toxicity, they are likely to prove
useful in the treatment of patients with genetically defined NSCLC.
Antiangiogenic Receptor TKIs
A second class of RTKs that has received significant attention for
targeted chemotherapy is the proangiogenic RTKs. This group of
receptors is primarily composed of the vascular endothelial growth
factor receptor (VEGFR) and platelet-derived growth factor receptor
(PDGFR) families, each of which contains three distinct members
[89,90]. The FGFR family may also be considered in this category,
although its effects in lung cancers are more traditionally associated
with tumor cell proliferation and survival rather than endothelial cell
proliferation and angiogenesis [91,92]. Several TKIs targeted to the
FGFR family are in clinical development (Table 2), only results for
dovitinib, which selectively targets FGFR1-3, in addition to VEGFR,
PDGFR, and other tyrosine kinases, have been reported to date [93].
As such, discussion of antiangiogenic TKI can be limited to VEGFR
and PDGFR families because these receptors have been the major
focus of ongoing antiangiogenic therapy [94].
The first Food and Drug Administration–approved small-molecule
angiogenesis inhibitors were the TKIs sorafenib and sunitinib, which
are both currently indicated for the treatment of metastatic renal tu-
mors and gastrointestinal stromal tumors and hepatocellular carcinoma
(sorafenib only) [95]. Whereas both drugs are primarily intended to
target VEGF-dependent endothelial cell proliferation and angiogenesis
owing to their potent inhibition of the VEGFR family, they also in-
hibit a number of other tyrosine kinases including KIT and members
of the PDGFR family (Table 3). In addition, both drugs have been
Table 3. Polypharmacologic TKIs in Development for NSCLC Treatment.
Name Manufacturer Known Targets Developmental Phase
Sorafenib Bayer/Onyx VEGFR, PDGFR, RAF, KIT 2/3
Sunitinib Pfizer VEGFR, PDGFR, KIT,
RET, FLT3
3
Imatinib Novartis BCR-ABL, PDGFRb, KIT, RET 2
Vandetanib AstraZeneca VEGFR, EGFR 3
Intedanib Boehringer Ingelheim FGFR, VEGFR, PDGFR 2/3
Dasatinib Bristol-Myers Squibb SRC family kinases 1/2
Pazopanib GlaxoSmithKline VEGFR, PDGFR, KIT 2
Lapatinib GlaxoSmithKline EGFR, HER2 2
XL-184 Exelixis MET, RET, VEGFR2 1/2
BIBW2992 Boehringer Ingelheim EGFR, HER2 2
Foretinib GlaxoSmithKline MET, VEGFR2 1/2
Crizotinib Pfizer MET, ALK 3
XL-647 Exelixis EGFR, HER2, VEGFR, EPHB4 2
XL-228 Exelixis IGF1R, SRC, BCR-ABL 1
Lestaurtinib Cephalon JAK2, FLT4, TRK 1/2
PF04554878 Pfizer FAK, PYK2 1
Many of the TKIs currently in clinical development target multiple kinases. Validated targets for
each drug are indicated to the right, along with the stage of clinical testing each drug was in at the
time this article was prepared.
Table 2. Tyrosine Kinase Targets in Development for NSCLC Treatment.
Target Drug
RTKs
EGFR Vandetanib, lapatinib, BIBW2992, PF299804 (pan ERBB family)
MET Foretinib, crizotinib, ARQ197, XL184
ALK Crizotinib
FGFR Intedanib, BGJ398 (pan), dovitinib, AZD4547
IGF1R BMS754807, XL228
VEGFR Sorafenib, sunitinib, vandetanib, pazopanib, vatalanib, foretinib, intedanib
PDGFR Pazopanib, intedanib
KIT Imatinib
EPHB4 XL647
NRTKs
SRC Dasatinib, XL228
FAK GSK2256098, PF04554878, PF562271
JAK INCB018424, lestaurtinib
Tyrosine kinases that are commonly altered in NSCLC are being targeted for therapy with several
different TKIs. Drugs that are currently approved for therapy or are in clinical development are
listed at the right of the indicated tyrosine kinase.
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shown to inhibit different serine-threonine kinases at physiologically
relevant levels for cancer therapy [96,97]. This is particularly impor-
tant for sorafenib, which was originally designed as a BRAF inhibitor.
It is likely that this activity—and not its antiangiogenic potential—
explains recent reports of modest sorafenib efficacy in KRAS mutant
lung cancers in phase 2 clinical trials [98–100].
In addition to sorafenib and sunitinib, several other TKIs are in
various stages of clinical development for antiangiogenic NSCLC ther-
apy. All of these compounds target various members of the VEGFR
family—most prominently KDR/VEGFR2—as well as other RTKs
that have been implicated in NSCLC or other solid tumors (Tables 2
and 3) [101]. One of these agents, pazopanib (approved for use
in kidney cancer), shows selectivity for VEGFR, PDGFR, and KIT
and may prove to be useful for treating tumors that develop sec-
ondary resistance to treatment with sorafenib or sunitinib [102,103].
Newer TKIs that target both VEGFR and growth factor receptors
include vandetanib and foretinib, which demonstrate selectivity for
EGFR and MET, respectively [104–107]. Whereas both of these
drugs are still in the early phases of clinical testing, they hold signif-
icant promise as dual inhibitors of primary tumor cell proliferation/
survival and angiogenesis.
In addition to serving as traditional antiangiogenic compounds,
drugs that target PDGFR family members may also be beneficial as
adjuvant therapies owing to their ability to promote delivery of stan-
dard cytotoxic chemotherapies to tumors. Recent studies in NSCLC
xenografts have demonstrated that combined treatment of tumors with
imatinib—which inhibits PDGFRβ—and cytotoxic drugs including
taxanes, doxorubicin, or etoposide leads to more effective tumor cell
killing than any of the cytotoxic drugs alone [108]. This effect likely
results from loss of interstitial vascular pressure and microvessel leaki-
ness induced by imatinib treatment, which allows better penetration
of drugs into tumors. A phase 2/3 clinical trial with pazopanib in-
tended to test this preclinical model in stage I NSCLC patients is on-
going and should provide answers in the next year [109].
Although no information on resistance of NSCLC to antiangio-
genic TKIs is available because of the relative infancy of this therapy
in lung cancer patients, potential mechanisms for acquired resistance
to sunitinib have been described in the context of renal carcinoma
where this drug has been in use for a longer period. These mecha-
nisms are briefly described below.
Resistance Mechanism 4: Angiogenic Compensation
Traditional models of tumor angiogenesis suggest that primary tu-
mor cells promote increased vascularization by producing proangio-
genic factors such as VEGF, which recruit adjacent endothelial cells
to dissociate from stable vessels, migrate into the tumor, and pro-
liferate to from new blood vessels. Antiangiogenic TKIs such as
sunitinib disrupt this paracrine signaling loop by inhibiting VEGFR
and PDGFR activation in endothelial cells, resulting in decreased en-
dothelial cell recruitment and/or collapse of immature tumor vascu-
lature. Because endothelial cells—and not cancer cells—are the target
of drug treatment, secondary mutations to angiogenic receptors are
unlikely to account for resistance.
A recent xenograft model of acquired resistance to sunitinib has
been described for renal cell carcinoma in which tumor cells instead
compensate for loss of VEGF signaling by upregulating signaling by
the cytokine interleukin-8 (IL-8) [110]. This mechanism fits with pre-
vious work showing that various cytokines including IL-8 can elicit an
alternative mode of angiogenesis independent of VEGF [111,112].
Whether this mechanism plays a role in patients who relapse after ini-
tial response to sunitinib is unclear at this point, although results from
this study and others suggest that IL-8 levels may be enhanced in the
tumors of patients who demonstrated primary resistance to antiangio-
genic therapy [113].
Resistance Mechanism 5: Reversible Cellular
Identity Switching
The ability of epithelial-derived cancer cells to detach from pri-
mary tumors and metastasize to distant locations is associated with a
reversible change in cellular identity termed an epithelial-mesenchymal
transition (EMT) [114]. EMT is characterized by broad changes in
gene expression, cellular morphology, and migratory behavior in which
stationary epithelial cells assume the characteristics of migratory mes-
enchymal cells. Whereas EMT can be induced in a controlled manner
by the exposure of transformed cells to specific signaling ligands such
as those from the transforming growth factor beta (TGFβ) family,
several studies have shown that EMT also occurs spontaneously in
tumors and may be associated with drug resistance [115].
Evidence that reversible EMTmay underlie acquired sunitinib re-
sistance was described in a recent study in which cells derived from a
sunitinib-resistant renal tumor metastasis with mesenchymal features
were explanted to tissue culture and then xenografted into athymic
nude mice [116]. Surprisingly, xenografted cells reverted to a sunitinib-
sensitive state and demonstrated phenotypic reversion to an epithelial
identity. Although the precise reason for the reversion was not ex-
plored, it is likely that the tumor cells reverted to an epithelial pheno-
type during tissue culture because of the enhanced proliferative
capacity associated with this cellular identity.
It is interesting to note that the reversible changes in cellular pheno-
type that encompass EMT, such as decreased cellular proliferation
and nonrandom epigenetic alterations, are strikingly similar in nature
to those described for resistance to erlotinib [67,72]. Because these
changes in identity also promote resistance to cytotoxic chemothera-
pies, it might be suggested that a single mechanism is responsible for
driving several of the behaviors associated with aggressive solid tumor
growth [115]. The clinical implications of this hypothesis are critically
important because they suggest that prevention of identity switching in
primary tumors may prove to be an effective therapy to inhibit drug
resistance and seeding of secondary tumors to distant locations [117].
Further studies combining HDAC inhibitors with targeted agents in-
cluding TKI will be necessary to test this hypothesis in the clinic. One
phase 2 study of a HDAC inhibitor (entinostat) in combination with
erlotinib has completed accrual, and results are pending [118].
Nonreceptor TKIs
Although the RTK class of kinases has received significantly greater
attention as targets for NSCLC therapy, several nonreceptor tyrosine
kinases (NRTKs) are also implicated in the cause and progression of
this disease [3]. NRTKs primarily serve as secondary messengers to
relay extracellular signals from growth factor, cytokine, and adhesion
receptors to a wide array of targets in the cytoplasm and nucleus.
Similar to RTK, these kinases can be activated by different genetic
mechanisms including genomic amplification, point mutation, and
translocation (Figure 1 and Table 1) [16]. In addition, they can also
be strongly activated by dysregulated RTK signaling in the absence of
genomic alteration. These mechanisms are proposed to alter kinase
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activity in a manner that promotes tumor cell proliferation and sur-
vival or changes in tumor cell adhesion and migratory capacity.
For the purposes of this discussion, we will focus on three classes
of NRTKs that are currently under development as targets for TKI
therapy. Although only two of these classes are currently being tar-
geted in ongoing clinical trials specific to NSCLC, all three are in
various stages of clinical testing as chemotherapeutic targets. Both
the rationale for targeting these kinases and the TKIs that are being
used for this purpose are discussed below.
SRC Family Inhibitors
Seminal work by Spector et al. [119] in the late 1970s demonstrated
that cancer is initiated by mutagenic changes to normal genes (“proto-
oncogenes”) found in the human cell. The focus of their work was the
sarcoma viral oncogene (v-Src), which was first associated with trans-
forming avian leukosis viruses, and then later found to have a nor-
mal cellular counterpart in human cells called c-Src, or simply SRC
in current genomic nomenclature [120]. Since then, genome sequenc-
ing studies from several species have demonstrated that SRC is part of
a larger family of nine related NRTKs, all of which have been impli-
cated in various cancer-relating signaling processes in a wide variety cell
and tissue types [16,121].
While activating mutations to SRC family members have been re-
ported for a wide variety of solid tumors, it is now recognized that
Src family oncoproteins are more commonly activated downstream
of other signaling pathways—particularly activated RTK—in cancer
[122]. Because Src plays an important role in tumor cell survival, ad-
hesion, migration, and invasion, it is an attractive target for rationally
designed NSCLC therapy [123]. Two small-molecule inhibitors of
Src—dasatinib and XL-228—are currently in clinical development
as single or combined agents for treatment of NSCLC (Table 3)
[124,125]. Although dasatinib also shows selectivity for the tyrosine
kinase ABL, it is primarily being developed as a SRC family kinase
inhibitor for cancer therapy [126]. XL-228 shows similar selectivity
for SRC but is primarily being developed as an inhibitor of the BCR-
ABL fusion protein and IGF1R owing to its higher specificity for
these kinases. Both preclinical models and early clinical trials with
dasatinib suggest that coordinate targeting of EGFR and Src may
be a useful therapeutic paradigm for the treatment of EGFR-positive
NSCLC [127,128].
Focal Adhesion Kinase Inhibitors
Signaling by the integrin family of adhesion receptors is critical for
survival of both normal and transformed cells [129]. Activated integ-
rins usually transmit these signals in the context of large protein com-
plexes such as focal adhesions, which contain a variety of signaling
enzymes including serine/threonine and tyrosine kinases [130].
Key mediators of survival signaling downstream of integrins include
the closely related tyrosine kinases FAK and PYK2. Inhibition of sig-
naling by these kinases induces cell death in a variety of tumor lines,
consistent with their necessity for cellular viability [131].
Three different TKIs targeted to FAK and PYK2 are currently being
evaluated in phase 1 clinical trials as single-agent therapies, although
none of these drugs are specifically being used for the treatment of
NSCLC (Table 2) [132,133]. Because FAK signaling has been im-
plicated survival of several NSCLC cell lines, however, these drugs
may find use as single or combined therapeutics for the treatment of
this disease.
Janus Kinase Inhibitors
The Janus kinase ( JAK) family of proteins is composed of four sep-
arate tyrosine kinases that primarily function to transmit signals from
cytokine receptors to their cytoplasmic and nuclear effectors. The most
well-characterized targets of JAK family kinases are the signal trans-
ducer and activator of transcription (STAT) family of proteins, which
translocate to the nucleus and induce transcription of key target genes
in response to tyrosine phosphorylation [134]. Both JAK and STAT
proteins are implicated in a wide variety of cancer-associated processes,
most notably cell survival, angiogenesis, and immune surveillance.
JAK family kinases have primarily been implicated in hematologic
malignancies, particularly in the case of JAK2, which is mutated in
myeloproliferative disorders [135]. Emerging evidence suggests, how-
ever, that JAK/STAT signaling may play a wider role in NSCLC than
has been previously appreciated because many NSCLC cell lines and
patient tumors demonstrate elevated levels of JAK2 activity or STAT
phosphorylation [136,137]. Two potential mechanisms to explain
this effect are the selective epigenetic silencing of the suppressor of
cytokine signaling-3 (SOCS3) promoter or genetic loss of the phos-
phatase PTPRD in NSCLC cells, both of which effectively increase
JAK activity by removing critical negative feedback loops required to
silence the activity of STAT proteins [138–140]. These findings have
yet to be translated into the clinic for NSCLC treatment, although
multiple JAK inhibitors are currently undergoing phase 1/2 testing
for the treatment of other malignancies (Table 2) [141–144].
Future Directions in TKI Therapy for NSCLC
Although many of the TKI discussed above are in relatively early
stages of clinical testing, data that have already emerged from these
studies suggest that rationally designed use of these agents will likely
be effective in treating subsets of patients with specific combinations
of genetic “driver mutations” [145]. Much work will be required to
effectively determine which patients are the correct candidates for
any given therapy, however, because it is now clear that simple ex-
pression and/or activation of a given target—for example, EGFR—
is insufficient to predict patient responsiveness to inhibitors. This
will require extensive genetic comparison of responders and non-
responders, which in turn depends on further advances in sequenc-
ing technology that make such comparisons feasible [146].
A key theme that has clearly emerged from clinical studies of var-
ious TKIs is the necessity of inhibiting multiple targets in parallel
to prevent the acquisition of drug resistance. In some respects, this
should have been obvious based on the wealth of literature regarding
antibiotic resistance in bacteria and viruses, which, in some instances,
occurs by mechanisms that are remarkably similar to those discovered
for EGFR TKI resistance [147,148]. Targeting of multiple kinases in
parallel can be achieved by combining several highly specific drugs or
by use of inhibitors that selectively target multiple targets [149]. The
latter class of drugs has become especially popular in recent years
because most kinase inhibitors function as nucleotide mimetics and,
as a result, often demonstrate selectivity for more than one target
(Table 3) [150]. Intentional use of these so-called “polypharmaco-
logics” to interfere with multiple RTKs or multiple cancer-related pro-
cesses such as tumor cell proliferation and angiogenesis has recently
gained wider acceptance and is likely to see further development in
the near future [151].
Another approach to rationally designed chemotherapy that has
seen increased attention of late focuses on combination of compounds
that target commonly activated pathways rather than individual
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oncogenic molecules [38]. Because many of the RTKs that have been
implicated in NSCLC activate similar downstream effectors, tar-
geting common pathways rather than multiple receptors may be a
more effective alternative for chemotherapy [152,153]. Several drugs
that inhibit the Ras/MAPK, PI3K/Akt, mTOR, and JAK/STAT path-
ways are in clinical development as single or combined agents. Use of
these drugs may turn out to be more effective than targeting individ-
ual RTKs because the mutational spectrum for receptors is signifi-
cantly wider than the number of signaling pathways activated by
these molecules.
The question of whether targeted therapeutics will provide addi-
tional benefit in combination with radiotherapy (XRT) or cytotoxic
chemotherapy (CC) is also of great clinical interest because XRTand/
or CC remain the standard of care for unresectable or advanced
NSCLC. Several phase 2/3 clinical trials have begun to address this
question by concurrent use of sorafenib or various EGFR inhibitors
with CC agents, including platinum-based drugs, DNA-damaging
agents, and taxanes [47,154–157], or in combination with XRT
[158,159]. Results from these studies have been almost uniformly
disappointing and demonstrate little, if any, additional benefit of
combined therapy over CC or combined CC and XRT alone. Be-
cause most of these studies were performed in unselected patient
populations, however, it remains to be seen whether combinational
treatment with CC or XRT and targeted therapeutics will improve
outcome in patients with genetically defined lesions. It has also been
suggested that any potential benefit from combinatorial treatment is
more likely to emerge from serial—rather than concurrent—treatment
or maintenance CC because targeted drugs including TKIs often
induce a cytostatic response that can antagonize the proliferation-
dependent mechanisms of cell killing by traditional cytotoxic therapies
when used concurrently [160].
Regardless of which therapeutic paradigm turns out to be most ef-
fective, it is clear that NSCLC will have to be treated with a “person-
alized medicine” approach if chemotherapy is to be widely successful
in the clinic. This approach requires that each patient be segregated
into a specific treatment group according to the constellation of mo-
lecular alterations that define his or her disease [161]. Whereas the
most tangible methods for segregation currently rely on limited se-
quencing and gene expression data, it is likely that more sophisticated
approaches including whole-genome sequencing, epigenome profiling,
proteome profiling, and microRNA profiling (miRome profiling) will
eventually be used to provide a more complete picture of lung cancer
biology. Although this entire panel of analyses is unlikely to find clin-
ical utility in the near future, incremental introduction of each tech-
nique into clinical practice will help to better focus rationally designed
therapies on the patients who will most benefit from them.
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